These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27599816)

  • 21. Comparing auditory, visual and vibrotactile cues in individuals with Parkinson's disease for reducing risk of falling over different types of soil.
    Ayena JC; Tremblay LE; Otis MJ; Ménélas BJ
    Somatosens Mot Res; 2017 Dec; 34(4):226-234. PubMed ID: 29318933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivastigmine for dementia associated with Parkinson's disease.
    Morgan J; Sethi KD
    Curr Neurol Neurosci Rep; 2005 Jul; 5(4):263-5. PubMed ID: 15987609
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
    Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
    Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin injections do not improve freezing of gait in Parkinson disease.
    Wieler M; Camicioli R; Jones CA; Martin WR
    Neurology; 2005 Aug; 65(4):626-8. PubMed ID: 16116132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
    Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atomoxetine for freezing of gait in Parkinson disease.
    Jankovic J
    J Neurol Sci; 2009 Sep; 284(1-2):177-8. PubMed ID: 19361809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gait disorders and balance disturbances in Parkinson's disease: clinical update and pathophysiology.
    Boonstra TA; van der Kooij H; Munneke M; Bloem BR
    Curr Opin Neurol; 2008 Aug; 21(4):461-71. PubMed ID: 18607208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paradoxical gait at a narrowed entrance in a patient with Hoehn-Yahr stage III Parkinson's disease.
    Kataoka H; Tanaka N; Kiriyama T; Eura N; Horikawa H; Ikada Y; Ueno S
    Eur Neurol; 2012; 68(5):276-8. PubMed ID: 23051756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease.
    Di Giacopo R; Fasano A; Quaranta D; Della Marca G; Bove F; Bentivoglio AR
    Mov Disord; 2012 Apr; 27(4):559-61. PubMed ID: 22290743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of falls and fear of falling on health-related quality of life in patients with Parkinson's disease.
    Grimbergen YA; Schrag A; Mazibrada G; Borm GF; Bloem BR
    J Parkinsons Dis; 2013 Jan; 3(3):409-13. PubMed ID: 23948987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
    Wesnes K
    Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
    Ballard C; Lane R; Barone P; Ferrara R; Tekin S
    Int J Clin Pract; 2006 Jun; 60(6):639-45. PubMed ID: 16805745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.
    Yarnall AJ
    Neurodegener Dis Manag; 2014; 4(2):127-36. PubMed ID: 24832030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive resistance training improves gait initiation in individuals with Parkinson's disease.
    Hass CJ; Buckley TA; Pitsikoulis C; Barthelemy EJ
    Gait Posture; 2012 Apr; 35(4):669-73. PubMed ID: 22266107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Collapse in the elderly: rivastigmine-induced heart block and a literature review of the pharmacology of acetylcholinesterase inhibitors used in Alzheimer's disease.
    Alonge O; Iqbal FM; Cifonelli E
    BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29666099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
    Rahimi F; Roberts AC; Jog M
    Clin Neurol Neurosurg; 2016 Nov; 150():117-124. PubMed ID: 27618783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spatiotemporal Gait Variables Using Wavelets for an Objective Analysis of Parkinson Disease.
    Castaño Y; Arango J; Navarro A
    Stud Health Technol Inform; 2018; 249():173-178. PubMed ID: 29866976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.